Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with XXXX agents for @entity5 .

@entity1 @entity5 @entity8082 @entity3003 @entity900 @entity157 @entity902
BACKGROUND: The effectiveness of additional chemotherapy in preventing @entity5 recurrence of @entity157 ( @entity157 ) has not been fully established. The authors compared the efficacy of 2 @entity902 -based chemotherapeutic agents in combination with radical local treatment for preventing intrahepatic distant recurrence (IDR). METHODS: Seventy-eight @entity1 with stage I/II @entity157 aged 45 to 85 years underwent transcatheter arterial chemoembolization and/or radiofrequency ablation after they received hepatic arterial infusion (HAI) of @entity902 compounds. The HAI consisted of @entity8082 ( @entity3003 ) in 25 @entity1 and @entity900 ( @entity900 ) in 53 @entity1 . Multivariate analysis was used to identify independent factors that were associated with IDR. RESULTS: Cumulative IDR rates at 1 year, 2 years, and 3 years were 21.7%, 52.2% and 75.7%, respectively, in the @entity3003 group and 8.1%, 22.7%, and 36.9%, respectively, in the @entity900 group. The @entity900 group had a significantly lower IDR rate compared with the @entity3003 group. The selection of a @entity902 agent was 1 of the independent factors for IDR in a multivariate Cox proportional hazards model. CONCLUSIONS: HAI chemotherapy with @entity900 before radical local treatment was effective in @entity1 with @entity157 . The authors concluded that radical local treatment with concurrent HAI using @entity900 may contribute to a longer progression-free period, which could be predicted with intrahepatic imaging in @entity1 with stage I/II @entity157 .
